As for the deceased donor, potential living donors should be carefully evaluated to identify a previous history of malignancy or active neoplasia, based on a thorough medical history, physical examination and imaging tests. It should be noted that the risk of clinical and subclinical malignancy increases markedly with age and that the risk of different cancers differs among countries. Hence, screening for prevalent malignant diseases in the population should be based on national cancer screening protocols.
Follow-up of the living donor to detect and treat any complication related to donation and appearing in the short, mid- or long term is a recognized international standard. On the other hand, during the follow-up of the living donor, potentially transmissible diseases, including malignancies, might arise, which were not detected during the donor evaluation preceding transplantation. Cases of malignancies appearing in living donors shortly after donation have been described in the literature. This situation should lead to alerting the relevant teams. Needless to say, the procurement / transplant team should take care / responsibility of the live donors in terms of treatment and follow-up carea